Novo Nordisk seeks to block Mylan generic

22-08-2019

Rory O'Neill

Danish pharmaceutical company Novo Nordisk has sued Mylan in a US court over a proposed generic of diabetes drug Victoza (liraglutide).


Novo Nordisk, Mylan, US Food and Drug Administration, Victoza, diabetes, type 2 diabetes, US Department of Justice, ANDA, generic

LSIPR